Ohr Pharmaceuticals (OHRP) & Aevi Genomic Medicine (GNMX) Critical Analysis
Ohr Pharmaceuticals (NASDAQ: OHRP) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitabiliy, valuation, risk and earnings.
Insider & Institutional Ownership
8.3% of Ohr Pharmaceuticals shares are held by institutional investors. Comparatively, 28.0% of Aevi Genomic Medicine shares are held by institutional investors. 17.4% of Ohr Pharmaceuticals shares are held by company insiders. Comparatively, 24.8% of Aevi Genomic Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Ohr Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Valuation & Earnings
This table compares Ohr Pharmaceuticals and Aevi Genomic Medicine’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Ohr Pharmaceuticals||N/A||N/A||-$24.22 million||($0.70)||-0.87|
|Aevi Genomic Medicine||N/A||N/A||-$41.42 million||($1.15)||-1.14|
Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Ohr Pharmaceuticals and Aevi Genomic Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-108.08%||-95.41%|
This is a breakdown of current ratings and target prices for Ohr Pharmaceuticals and Aevi Genomic Medicine, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
Ohr Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 1,540.22%. Aevi Genomic Medicine has a consensus target price of $5.25, suggesting a potential upside of 300.76%. Given Ohr Pharmaceuticals’ higher probable upside, analysts plainly believe Ohr Pharmaceuticals is more favorable than Aevi Genomic Medicine.
Ohr Pharmaceuticals beats Aevi Genomic Medicine on 5 of the 8 factors compared between the two stocks.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.